Tristan T Timbrook1,2, Aisling R Caffrey1,2,3, Megan K Luther1,2,3, Vrishali Lopes1,3, Kerry L LaPlante1,2,3. 1. Rhode Island Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island. 2. College of Pharmacy, University of Rhode Island, Kingston, Rhode Island. 3. Center of Innovation in Long Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island.
Abstract
STUDY OBJECTIVE: Current guidelines recommend higher daptomycin doses than the daptomycin label dose of 6 mg/kg for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, the evidence supporting this recommendation is from in vitro and case series studies. This study evaluated the comparative effectiveness of the daptomycin label dose versus higher daptomycin doses in patients with MRSA bacteremia. DESIGN: Retrospective national cohort study. SETTING: Veterans Affairs medical centers. PATIENTS: A total of 371 adults with MRSA bacteremia who were admitted between 2002 and 2015 and treated initially with vancomycin within 24 hours of initial culture collection and then switched to daptomycin therapy within 7 days; 138 patients (37.2%) received daptomycin doses higher than the daptomycin label dose (7 mg/kg or greater), and 233 (62.8%) received the daptomycin label dose (6 mg/kg). MEASUREMENTS AND MAIN RESULTS: Clinical outcomes were compared among those who received the daptomycin label dose and those who received the higher dose using propensity score-matched Cox proportional hazards regression models. To identify dose partitioning associated with optimal survival, classification and regression tree (CART) analysis was used among patients, controlling for confounding with a 30-day mortality disease risk score. Propensity score-matched 30-day mortality was 8.6% (6/70 patients) among the higher dose group versus 18.6% (13/70 patients) among the label dose group (hazard ratio 0.31, 95% confidence interval 0.10-0.94). No significant differences were observed in inpatient mortality, length of stay, 30-day readmission, or 30-day S. aureus reinfection between groups. CART analysis resulted in doses of 7 mg/kg or greater providing benefit only among patients with higher (more than 51%) predicted probabilities of 30-day mortality (p<0.001). CONCLUSION: To our knowledge, this is the first comparative effectiveness study of daptomycin doses in patients with MRSA bacteremia. Survival benefits were observed with doses higher than the daptomycin label dose (7 mg/kg or greater) for the treatment of MRSA bacteremia. These data suggest that higher doses than the daptomycin label dose may be preferred over the label dose for improving clinical outcomes in patients with MRSA bacteremia.
STUDY OBJECTIVE: Current guidelines recommend higher daptomycin doses than the daptomycin label dose of 6 mg/kg for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, the evidence supporting this recommendation is from in vitro and case series studies. This study evaluated the comparative effectiveness of the daptomycin label dose versus higher daptomycin doses in patients with MRSA bacteremia. DESIGN: Retrospective national cohort study. SETTING: Veterans Affairs medical centers. PATIENTS: A total of 371 adults with MRSA bacteremia who were admitted between 2002 and 2015 and treated initially with vancomycin within 24 hours of initial culture collection and then switched to daptomycin therapy within 7 days; 138 patients (37.2%) received daptomycin doses higher than the daptomycin label dose (7 mg/kg or greater), and 233 (62.8%) received the daptomycin label dose (6 mg/kg). MEASUREMENTS AND MAIN RESULTS: Clinical outcomes were compared among those who received the daptomycin label dose and those who received the higher dose using propensity score-matched Cox proportional hazards regression models. To identify dose partitioning associated with optimal survival, classification and regression tree (CART) analysis was used among patients, controlling for confounding with a 30-day mortality disease risk score. Propensity score-matched 30-day mortality was 8.6% (6/70 patients) among the higher dose group versus 18.6% (13/70 patients) among the label dose group (hazard ratio 0.31, 95% confidence interval 0.10-0.94). No significant differences were observed in inpatient mortality, length of stay, 30-day readmission, or 30-day S. aureus reinfection between groups. CART analysis resulted in doses of 7 mg/kg or greater providing benefit only among patients with higher (more than 51%) predicted probabilities of 30-day mortality (p<0.001). CONCLUSION: To our knowledge, this is the first comparative effectiveness study of daptomycin doses in patients with MRSA bacteremia. Survival benefits were observed with doses higher than the daptomycin label dose (7 mg/kg or greater) for the treatment of MRSA bacteremia. These data suggest that higher doses than the daptomycin label dose may be preferred over the label dose for improving clinical outcomes in patients with MRSA bacteremia.
Authors: Nicholas A Turner; Smitha Zaharoff; Heather King; Scott Evans; Toshimitsu Hamasaki; Thomas Lodise; Varduhi Ghazaryan; Tatiana Beresnev; Todd Riccobene; Rinal Patel; Sarah B Doernberg; Urania Rappo; Vance G Fowler; Thomas L Holland Journal: Trials Date: 2022-05-16 Impact factor: 2.728
Authors: Maya Beganovic; Jaclyn A Cusumano; Vrishali Lopes; Kerry L LaPlante; Aisling R Caffrey Journal: Open Forum Infect Dis Date: 2019-06-06 Impact factor: 3.835
Authors: Marin L Schweizer; Kelly Richardson; Mary S Vaughan Sarrazin; Michihiko Goto; Daniel J Livorsi; Rajeshwari Nair; Bruce Alexander; Brice F Beck; Michael P Jones; Mireia Puig-Asensio; Daniel Suh; Madeline Ohl; Eli N Perencevich Journal: Clin Infect Dis Date: 2021-01-29 Impact factor: 9.079
Authors: Ashley N Fox; Winter J Smith; Katherine E Kupiec; Stephanie J Harding; Beth H Resman-Targoff; Stephen B Neely; Bryan P White; Ryan E Owens Journal: Ther Adv Infect Dis Date: 2019-01-30
Authors: Kamal Hamed; Marc Engelhardt; Mark E Jones; Mikael Saulay; Thomas L Holland; Harald Seifert; Vance G Fowler Journal: Future Microbiol Date: 2020-01-10 Impact factor: 3.165
Authors: Evan J Zasowski; Trang D Trinh; Kimberly C Claeys; Abdalhamid M Lagnf; Sahil Bhatia; Kenneth P Klinker; Michael P Veve; Sandy J Estrada; Scott T Johns; Adam J Sawyer; Vanthida Huang; Brandi LaFrance; Donald P Levine; Keith S Kaye; Susan L Davis; Michael J Rybak Journal: Open Forum Infect Dis Date: 2021-12-23 Impact factor: 3.835